This observational pilot study is the first step in our program to build a recommendation engine to guide parents and HCPs to the most effective way to use cannabis to improve health and quality of life of children. This study is being led by the Cannformatics Inc. team and advisors Stephany Cox, PhD, and Dr. Myiesha Taylor, in collaboration with medical cannabis expert and author Dr. Bonni Goldstein.
MYIESHA TAYLOR, MD
View Bio >
STEPHANY COX, PhD
View Bio >
BONNI GOLDSTEIN, MD
Founder & Medical Director, Canna-Centers
Children diagnosed with ASD.
Currently using medical cannabis under HCP supervision.
Living in California (Los Angeles and San Francisco Bay Area).
Children’s data privacy is protected by HIPAA-compliant protocols.
ASD: Saliva collected from children pre- and post-consumption of regularly prescribed medical cannabis dosage.
Control: Saliva collected from age-matched neurotypical children.
Cannformatics’ proprietary platform identifies biomarkers that significantly changed pre- and post-consumption of medical cannabis.
Samples from neurotypical children are collected and analyzed to determine the biomarkers baseline for healthy physiological range.
Study participants will receive a report showing their individual changes in biomarkers related to ASD symptoms before and after medical cannabis consumption.
We will seek to publish the finding in a scientific peer-reviewed medical journal, across mainstream media and at Cannformatics.com.